FLT3 and acute myeloid leukemia: Midostaurin is reported to inhibit activating mutant forms of the human FMS-like tyrosine kinase-3 (FLT3) and is approved for the treatment of acute myeloid leukaemia bearing FLT3 activating mutations; it inhibits >90% AspH activity at 20 μM (Table 1, entry 6).